论文部分内容阅读
背景:设计了芬兰侵袭性肺炎球菌性疾病疫苗临床试验,以期评价肺炎球菌性疫苗的有效性,这种疫苗含有10种与流感嗜血杆菌蛋白D、破伤风类毒素及白喉类毒素作为载体蛋白相结合的血清型特异的多糖(PHiD-CV10)。方法:在这项随机、双盲现场研究中,大于19月龄的儿童或者接受PHiD-CV10疫苗,或者接受肝炎疫苗作为对照。在第一次接种中,小于7个月的婴儿接受3+1或2+1疫苗接种程序的接种,年龄为7~11个月的婴儿接受2剂疫苗接种。而那些12~
Background: A clinical trial of a Finnish invasive pneumococcal disease vaccine was designed to evaluate the efficacy of a pneumococcal vaccine containing 10 isolates of Haemophilus influenzae D, tetanus toxoid and diphtheria toxoid as carrier proteins The combination of serotype-specific polysaccharides (PHiD-CV10). Methods: In this randomized, double-blind, field study, children older than 19 months of age either received the PHiD-CV10 vaccine or received the hepatitis vaccine as a control. In the first vaccination, infants younger than 7 months were vaccinated with 3 + 1 or 2 + 1 vaccination programs and infants aged 7-11 months received 2 doses of vaccination. And those 12 ~